Although several studies have reported biomarkers, such as T cell repertoire, interleukin (IL)-6 levels, and IL-17 levels, that may predict the occurrence of irAEs, complete blood counts have recently been proposed to serve as markers of cancer inflammation and the adaptive immune response. Here, IL17A is linked to cancer.